Please provide your email address to receive an email when new articles are posted on . Triple therapy of vebicorvir, imdusiran and nucleos(t)ide reverse transcriptase inhibitor did not improve HBV ...
HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively As previously ...
Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the efficacy results hoped for in a midstage study. The investigational combo of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback